Cellsonics

Executive Summary

Cellsonics is a San Diego-based biotechnology company developing innovative medical devices for tissue dissociation. Its core technology, SimpleFlow, uses acoustic waves to create single-cell suspensions from tissue without enzymes or heat, preserving native cell biology. This platform addresses the critical upstream sample preparation market for cell therapy and single-cell analysis, offering a gentler, more consistent alternative to enzymatic and mechanical methods. Founded in 2017, Cellsonics has achieved regulatory approval (stage: 'Approved'), positioning it for commercial adoption. The market for tissue dissociation is growing rapidly with the expansion of cell therapies and single-cell genomics. Cellsonics' enzyme-free, label-free approach reduces variability and maintains cell viability, which is crucial for downstream applications. While the company is private and has not disclosed funding or valuation, its technology fills a clear need in cell therapy manufacturing and research. Near-term, Cellsonics is expected to scale its SimpleFlow platform through partnerships with cell therapy developers and expansion into new tissue types. Its success hinges on commercial traction and securing strategic collaborations to drive adoption in the fast-growing cell therapy ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major cell therapy developer60% success
• Q4 2026Regulatory clearance for a new tissue type (e.g., tumor samples)70% success
• H2 2026Series A or B funding round50% success